Literature DB >> 32258527

Genome editing technologies to treat rare liver diseases.

Marta Trevisan1, Giulia Masi1, Giorgio Palù1.   

Abstract

Liver has a central role in protein and lipid metabolism, and diseases involving hepatocytes have often repercussions on multiple organs and systems. Hepatic disorders are frequently characterized by production of defective or non-functional proteins, and traditional gene therapy approaches have been attempted for years to restore adequate protein levels through delivery of transgenes. Recently, many different genome editing platforms have been developed aimed at correcting at DNA level the defects underlying the diseases. In this Review we discuss the latest applications of these tools applied to develop therapeutic strategies for rare liver disorders, in particular updating the literature with the most recent strategies relying on base editors technology. 2020 Translational Gastroenterology and Hepatology. All rights reserved.

Entities:  

Keywords:  Rare liver diseases; base editors; gene therapy; genome editing; hepatocytes

Year:  2020        PMID: 32258527      PMCID: PMC7063531          DOI: 10.21037/tgh.2019.10.10

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  3 in total

1.  Rare and undiagnosed liver diseases: challenges and opportunities.

Authors:  Luca Fabris; Mario Strazzabosco
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 2.  Base editing: advances and therapeutic opportunities.

Authors:  Elizabeth M Porto; Alexis C Komor; Ian M Slaymaker; Gene W Yeo
Journal:  Nat Rev Drug Discov       Date:  2020-10-19       Impact factor: 112.288

3.  Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice.

Authors:  Michela Lisjak; Alessia De Caneva; Thibaut Marais; Elena Barbon; Maria Grazia Biferi; Fabiola Porro; Adi Barzel; Lorena Zentilin; Mark A Kay; Federico Mingozzi; Andrés F Muro
Journal:  Front Genome Ed       Date:  2022-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.